Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-09-17T09:58:56+00:00

The Dimerix Limited Clinical Trials – ACTION for Diabetic Kidney Disease and ACTION for Focal Segmental Glomerulosclerosis – Are Now Open!

Click Here For More Information

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Research

Our lead program DMX-200 is advancing through Phase 2 trials in patients with Chronic Kidney Disease (CKD).

Learn More

Technology

Our Receptor Heteromer Investigation Technology (Receptor-HIT) has been used by global pharmaceutical partners, and supported the development of our own DMX-200 program.

Learn More

Investors

Access the latest company news and information

Visit Investor Centre

Recent news and media

ASX: Dimerix Investor Update

See the ASX investor update presentation here.

Dimerix now recruiting patients for two phase 2 clinical trials in Diabetic Kidney Disease and a rare kidney scarring orphan disease

For more information please see media release.

Two Posters Presented at ANZSNASM

Dimerix have presented the following two posters at the ANZSNASM conference. ANZSNASM 2018 ACTION for DKD ANZSNASM 2018 ACTION for FSGS [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation

Home
Company
Program
Technology
Investors
Contact

© Copyright 2018 Dimerix | Credits

subscribe to patient updates

subscribe to news updates